Mod­er­na strikes $1.8B can­cer re­search deal with Im­mat­ics 

Mod­er­na has inked a deal worth up to $1.8 bil­lion with TCR spe­cial­ist Im­mat­ics that broad­ens the com­pa­ny’s po­si­tion in mR­NA-based can­cer re­search.

The Cam­bridge, MA-based mR­NA gi­ant has promised Im­mat­ics $120 mil­lion up­front and more than $1.7 bil­lion in de­vel­op­ment, reg­u­la­to­ry and com­mer­cial mile­stones for three re­search pro­grams, in­clud­ing one that com­bines Im­mat­ics’ most-de­vel­oped TCR-T can­di­date with a Mod­er­na can­cer vac­cine, ac­cord­ing to an SEC fil­ing on Mon­day morn­ing. The Im­mat­ics pro­gram, IMA203, read out promis­ing ear­ly da­ta in May in a small group of pa­tients with mul­ti­ple pre-treat­ed sol­id tu­mor types.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER